Nature’s Sunshine (NATR) Lays Out a $1B Growth Target Amid Guidance Cuts
Nature’s Sunshine Products (NATR) reported Q2 net sales of $117M and gross margin of 73.7%, its strongest second quarter. Management said North America digital sales rose 26% and subscription/autoship drove growth. It cut full-year net sales guidance to $490M-$500M and EBITDA to $48M-$52M, citing currency effects and a China sales reversal.
How this was made
The 30-second read
Why it matters
Investors must reconcile strong digital momentum and margin expansion with a China reversal and higher operating costs, which management says are driving lower sales and EBITDA targets.
Market read
The guidance cut (net sales and EBITDA ranges lowered) is the primary tradable takeaway, with China demand reversal and currency swings cited as causes.
What to watch
The article notes a planned North America direct-selling overhaul arriving in early 2027 and a CFO transition; execution timing and cost discipline could be the swing factors for the next several quarters.
Background
Nature's Sunshine held its Q2 earnings call on Aug 6 and delivered a record second quarter alongside a full-year guidance reset.
Ticker impact
Nature's Sunshine reported Q2 net sales of $117M and raised gross margin to 73.7%, but cut full-year sales and EBITDA guidance due to China reversal and currency swings.
Choppy to downside-biased reaction risk until investors get clarity on China operational issues and the timing of the North America direct-selling overhaul.
The article’s newest decision-relevant facts are the explicit full-year net sales and EBITDA guidance ranges being lowered, alongside specific regional deterioration (China -20%) and higher SG&A/incentives.
Market effects
Highlights risk for DTC and supplement/personal-care brands with international exposure, where FX and China demand swings can quickly reset guidance.
China weakness (-20% sales) is the key regional driver cited, implying heightened sensitivity to any follow-on China updates.
FX headwinds are explicitly cited, suggesting broader currency-driven volatility for multinational consumer health names.
Counterpoint
Digital growth and improving gross margin could indicate the guidance cut is more about temporary geography and FX than structural demand deterioration.
Key entities
- companyNature's Sunshine Products
NASDAQ-listed consumer health company that reported Q2 results and cut full-year sales and EBITDA guidance.
- executiveRuth Perkins
Named CFO effective September 1, adding a leadership change alongside the guidance reset.
- executiveJanine Weber
Named President of North America effective August 10, coinciding with plans to overhaul the direct-selling business.
